Tuesday, February 3, 2015

New molecule protects heart from toxic Breast Cancer drugs

A new molecule has been found that protects the heart from toxic breast cancer drugs and also kills the cancerous tumor. The research from Italy addresses the burgeoning problem of heart disease in cancer survivors and is announced by the European Society of Cardiology today on World Cancer Day.
Dr Alessandra Ghigo, first author and research fellow in the Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy, said: "Cardiotoxicity of has become an increasing problem in the last decade due to the increasing success of and aggressive use of these drugs. More people are now surviving cancer but it is estimated that 32% of them could die of caused by their treatment. This has led to a new field of medicine called cardio-oncology." Professor Patrizio Lancellotti, chair of the ESC EACVI/HFA Cardiac Oncology Toxicity Registry, said: "Patients with some forms of are at greater risk of dying from heart disease than from cancer. A number of breast cancer treatments are toxic for the heart notably chemotherapy with anthracyclines, such as doxorubicin, or with trastuzumab (Herceptin). Radiation therapy can make anthracyclines even more cardiotoxic, as can the sequence of anthracylines followed by trastuzumab. The latter combination for metastatic breast cancer can cause severe heart failure in up to 27% of patients."This means we could use an inhibitor of PI3Kγ to both protect the heart from doxorubicin and prevent tumor growth. Our research shows that inhibiting PI3Kγ stops inflammation in the tumor and kills the tumor."
She concluded: "The mechanisms underlying heart failure induced by anticancer therapies are different to those underlying heart failure from other causes such as hypertension. For this reason there are no effective drugs on the market to prevent this new kind of heart failure. Our study shows that PI3Kγ could be a novel way to prevent caused by cancer drugs while also helping to kill the tumor itself."

No comments:

Post a Comment